Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVVI: Immunosenescence and HBV Vaccine Efficacy in Chronic Renal Disease
NCT02375711Terminated
- Sponsor
- CHU de Besançon
- Start
- Mar 2014
- Primary completion
- Sep 2016
- Countries
- 1
01
Overview
Single-arm trial, sponsored by CHU de Besançon. Primary endpoint: Cluster of Differentiation (CD) 8+ CD 57+ CD 28- / CD 8+ T lymphocytes Ratio in Peripheral Blood at 13 months. Started Mar 2014; status: terminated.
Beyond the preview
Go deeper on NCT02375711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375711.